RE:TLT Successfully Completes Non-GLP Toxicity Study for GBMNice, this paves the way for a deal with Big Pharma on many more indications through IV administration of Rutherin. "The GLP toxicology program that Theralase® is completing will lay the groundwork for Rutherrin® to be IV administered for numerous other cancers; including: Non-Small Cell Lung Cancer ("NSCLC"), pancreatic cancer, prostate cancer, kidney cancer and colorectal cancer. I look forward to commencing the clinical study program evaluation of this versatile and effective drug in 2024.""